Previous 10 | Next 10 |
HILLSIDE, NJ / ACCESSWIRE / June 21, 2022 / Integrated BioPharma, Inc. (OTCQX:INBP) (the "Company" or "INBP") announced today Mr. Carl DeSantis has resigned as a Class I Director from the Company's Board of Directors and Mr. Damon DeSantis, has been elected to serve as a Class I Director t...
HILLSIDE, NJ / ACCESSWIRE / May 12, 2022 / Integrated BioPharma, Inc. (OTCQX:INBP) (the "Company" or "INBP") reports its financial results for the fiscal quarter ended March 31, 2022. Revenue for the three-month period ended March 31, 2022 was $15.6 million compared to $17.1 million for the...
Integrated BioPharma press release (OTCQX:INBP): FQ2 GAAP EPS of $0.03. Revenue of $14.6M (+2.4% Y/Y). For further details see: Integrated BioPharma GAAP EPS of $0.03, revenue of $14.6M
HILLSIDE, NJ / ACCESSWIRE / February 10, 2022 / Integrated BioPharma, Inc. (OTCQX:INBP) (the "Company" or "INBP") reports its financial results for the quarter ended December 31, 2021. Revenue for the quarter ended December 31, 2021 was $14.6 million compared to $14.3 million for the quarte...
HILLSIDE, NJ / ACCESSWIRE / November 10, 2021 / Integrated BioPharma, Inc. (OTCQX:INBP) (the "Company" or "INBP") reports its financial results for the quarter ended September 30, 2021. Revenue for the quarter ended September 30, 2021 was $12.8 million compared to $15.2 million for the quar...
HILLSIDE, NJ / ACCESSWIRE / September 2, 2021 / Integrated BioPharma, Inc. (OTCQX:INBP) (the "Company" or "INBP") reports its financial results for the quarter and fiscal year ended June 30, 2021. Revenue for the quarter ended June 30, 2021 was $17.1 million compared to $13.5 million for th...
Integrated BioPharma (INBP): FQ3 GAAP EPS of $0.04.Revenue of $17.1M (+25.7% Y/Y)Press Release For further details see: Integrated BioPharma reports FQ3 results
HILLSIDE, NJ / ACCESSWIRE / May 13, 2021 / Integrated BioPharma, Inc. ((OTCQX:INBP)) (the "Company" or "INBP") reports its financial results for the quarter ended March 31, 2021. Revenue for the quarter ended March 31, 2021 was $17.1 million compared to $13.6 million for the quarter ended...
OTC Markets Group Announces Quarterly Index Performance and Rebalancing PR Newswire NEW YORK , April 15, 2021 /PRNewswire/ -- OTC Markets Group Inc. (OTCQX: OTCM), operator of financial markets for 11,000 U.S. and global securities, today announced the first ...
Integrated BioPharma Announces Launch of Investors Website HILLSIDE, NJ / ACCESSWIRE / April 8, 2021 / Integrated BioPharma, Inc. (OTCQX:INBP) (the "Company" or "INBP") announces the launch of an updated investors website. "As part of our efforts in supporting Integrated BioPharma, Inc...
News, Short Squeeze, Breakout and More Instantly...
Integrated Biopharma Inc Company Name:
INBP Stock Symbol:
OTCMKTS Market:
HILLSIDE, NJ / ACCESSWIRE / May 10, 2024 / Integrated BioPharma, Inc. (OTCQX:INBP) (the "Company" or "INBP") reports its financial results for the quarter ended March 31, 2024. Revenue for each of the quarters ended March 31, 2024 and 2023 were approximately $13.1 million. The Company had opera...
AlloVir Inc. (ALVR) is expected to report $-0.16 for Q1 2024 Inter & Co. Inc. (INTR) is expected to report $0.08 for Q1 2024 Array Technologies Inc. (ARRY) is expected to report $-0.06 for Q1 2024 Sphere 3D Corp. (ANY) is expected to report $-0.23 for Q1 2024 Alpine Immune Sci...
HILLSIDE, NJ / ACCESSWIRE / February 12, 2024 / Integrated BioPharma, Inc. (OTCQX:INBP) (the "Company" or "INBP") reports its financial results for the quarter ended December 31, 2023. Revenue for the quarter ended December 31, 2023 was $11.5 million compared to $12.3 million for the quarter ...